{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:58:13Z","timestamp":1790794693018,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K09213"],"award-info":[{"award-number":["22K09213"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K16667"],"award-info":[{"award-number":["22K16667"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Glioblastoma (GBM) is the most common malignant brain tumor and has \u201cimmunologically cold\u201d features. Changing GBM to an \u201cimmunologically hot\u201d tumor requires a strong trigger that induces initial immune responses in GBM. Allogeneic natural killer cells (NKCs) have gained considerable attention as promising immunotherapeutic tools against cancer, where gene-edited NKCs would result in effective anti-cancer treatment. The present study focused on the immune checkpoint molecule cytokine-inducible SH2-containing protein (CISH, or CIS) as a critical negative regulator in NKCs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The GBM tumor environment featured with immunological aspect was analyzed with Cancer immunogram and GlioVis. We generated human primary CIS-deleted NKCs (NK dCIS) using clustered regularly interspaced short palindromic repeats\/CRISPR-associated protein 9 (CRISPR\/Cas9) with single guide RNA targeting genome sites on CIS coding exons. The genome-edited NKCs underwent microarray with differential expression analysis and gene set enrichment analysis (GSEA). The anti-GBM activity of the genome-edited NKCs was evaluated by apoptosis induction effects against allogeneic GBM cells and spheroids. We further\u00a0detected in vivo antitumor effects using xenograft brain tumor mice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We successfully induced human CIS-deleted NKCs (NK dCIS) by combining our specific human NKC expansion method available for clinical application and genome editing technology. <jats:italic>CIS<\/jats:italic> gene-specific guide RNA\/Cas9 protein complex suppressed CIS expression in the expanded NKCs with high expansion efficacy. Comprehensive gene expression analysis demonstrated increased expression of 265 genes and decreased expression of 86 genes in the NK dCIS. Gene set enrichment analysis revealed that the enriched genes were involved in NKC effector functions. Functional analysis revealed that the NK dCIS had increased interferon (IFN)\u0264 and tumor necrosis factor (TNF) production. <jats:italic>CIS<\/jats:italic> deletion enhanced NKC-mediated apoptosis induction against allogeneic GBM cells and spheroids. Intracranial administration of the allogeneic NKCs prolonged the overall survival of xenograft brain tumor mice. Furthermore, the NK dCIS extended the overall survival of the mice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The findings demonstrated the successful induction of human primary NK dCIS with CRISPR\/Cas9 with efficient expansion. <jats:italic>CIS<\/jats:italic> deletion enhanced the NKC-mediated anti-tumor effects in allogeneic GBM and could be a promising immunotherapeutic alternative for patients with GBM.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-023-02770-6","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T06:03:38Z","timestamp":1691647418000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["CIS deletion by CRISPR\/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma"],"prefix":"10.1186","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4286-9356","authenticated-orcid":false,"given":"Tsutomu","family":"Nakazawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Maeoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutoshi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Ouji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nakase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Tsujimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"issue":"8","key":"2770_CR1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231\u201351.","journal-title":"Neuro Oncol"},{"issue":"10","key":"2770_CR2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396.","journal-title":"N Engl J Med"},{"issue":"9","key":"2770_CR3","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jamaoncol.2018.1789","volume":"4","author":"QT Ostrom","year":"2018","unstructured":"Ostrom QT, Cote DJ, Ascha M, Kruchko C, Barnholtz-Sloan JS. Adult glioma incidence and survival by race or ethnicity in the United States From 2000 to 2014. JAMA Oncol. 2018;4(9):1254\u201362.","journal-title":"JAMA Oncol"},{"issue":"23","key":"2770_CR4","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306\u201316.","journal-title":"JAMA"},{"issue":"8","key":"2770_CR5","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","volume":"28","author":"T Todo","year":"2022","unstructured":"Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J, et al. Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: a phase 2 trial. Nat Med. 2022;28(8):1630\u20139.","journal-title":"Nat Med"},{"issue":"22","key":"2770_CR6","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med"},{"issue":"16","key":"2770_CR7","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535\u201346.","journal-title":"N Engl J Med"},{"issue":"26","key":"2770_CR8","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"7","key":"2770_CR9","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(7):1003\u201310.","journal-title":"JAMA Oncol"},{"issue":"11","key":"2770_CR10","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/neuonc\/noy032","volume":"20","author":"SJ Bagley","year":"2018","unstructured":"Bagley SJ, Desai AS, Linette GP, June CH, O\u2019Rourke DM. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. Neuro Oncol. 2018;20(11):1429\u201338.","journal-title":"Neuro Oncol"},{"issue":"3","key":"2770_CR11","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.3390\/ijms24032111","volume":"24","author":"T Morimoto","year":"2023","unstructured":"Morimoto T, Nakazawa T, Maeoka R, Nakagawa I, Tsujimura T, Matsuda R. Natural Killer Cell-Based Immunotherapy against Glioblastoma. Int J Mol Sci. 2023;24(3):2111.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2770_CR12","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","volume":"9","author":"E Vivier","year":"2008","unstructured":"Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9(5):503\u201310.","journal-title":"Nat Immunol"},{"issue":"19","key":"2770_CR13","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1158\/1078-0432.CCR-11-1347","volume":"17","author":"MR Parkhurst","year":"2011","unstructured":"Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res. 2011;17(19):6287\u201397.","journal-title":"Clin Cancer Res"},{"key":"2770_CR14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s12967-015-0632-8","volume":"13","author":"N Sakamoto","year":"2015","unstructured":"Sakamoto N, Ishikawa T, Kokura S, Okayama T, Oka K, Ideno M, et al. Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer. J Transl Med. 2015;13:277.","journal-title":"J Transl Med"},{"issue":"11","key":"2770_CR15","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1158\/1078-0432.CCR-03-0683","volume":"10","author":"SW Krause","year":"2004","unstructured":"Krause SW, Gastpar R, Andreesen R, Gross C, Ullrich H, Thonigs G, et al. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial. Clin Cancer Res. 2004;10(11):3699\u2013707.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2770_CR16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ni1581","volume":"9","author":"LL Lanier","year":"2008","unstructured":"Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9(5):495\u2013502.","journal-title":"Nat Immunol"},{"issue":"2","key":"2770_CR17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18(2):85\u2013100.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"2770_CR18","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19(3):200\u201318.","journal-title":"Nat Rev Drug Discov"},{"issue":"357","key":"2770_CR19","doi-asserted-by":"crossref","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","volume":"8","author":"R Romee","year":"2016","unstructured":"Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8(357):357ra123.","journal-title":"Sci Transl Med"},{"issue":"26","key":"2770_CR20","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017\u201323.","journal-title":"Blood"},{"issue":"7","key":"2770_CR21","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.cell.2020.05.007","volume":"181","author":"F Klemm","year":"2020","unstructured":"Klemm F, Maas RR, Bowman RL, Kornete M, Soukup K, Nassiri S, et al. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells. Cell. 2020;181(7):1643-60 e17.","journal-title":"Cell"},{"issue":"1","key":"2770_CR22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11060-020-03483-y","volume":"151","author":"MM Grabowski","year":"2021","unstructured":"Grabowski MM, Sankey EW, Ryan KJ, Chongsathidkiet P, Lorrey SJ, Wilkinson DS, et al. Immune suppression in gliomas. J Neurooncol. 2021;151(1):3\u201312.","journal-title":"J Neurooncol"},{"issue":"6096","key":"2770_CR23","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816\u201321.","journal-title":"Science"},{"issue":"10","key":"2770_CR24","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/nmeth.2649","volume":"10","author":"P Mali","year":"2013","unstructured":"Mali P, Esvelt KM, Church GM. Cas9 as a versatile tool for engineering biology. Nat Methods. 2013;10(10):957\u201363.","journal-title":"Nat Methods"},{"issue":"7","key":"2770_CR25","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ni.3470","volume":"17","author":"RB Delconte","year":"2016","unstructured":"Delconte RB, Kolesnik TB, Dagley LF, Rautela J, Shi W, Putz EM, et al. CIS is a potent checkpoint in NK cell-mediated tumor immunity. Nat Immunol. 2016;17(7):816\u201324.","journal-title":"Nat Immunol"},{"issue":"2","key":"2770_CR26","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","volume":"27","author":"H Zhu","year":"2020","unstructured":"Zhu H, Blum RH, Bernareggi D, Ask EH, Wu Z, Hoel HJ, et al. Metabolic reprograming via deletion of CISH in human iPSC-derived NK cells promotes in vivo persistence and enhances anti-tumor activity. Cell Stem Cell. 2020;27(2):224-237.e6.","journal-title":"Cell Stem Cell."},{"issue":"5","key":"2770_CR27","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.2020007748","volume":"137","author":"M Daher","year":"2021","unstructured":"Daher M, Basar R, Gokdemir E, Baran N, Uprety N, Nunez Cortes AK, et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood. 2021;137(5):624\u201336.","journal-title":"Blood"},{"issue":"4","key":"2770_CR28","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/JLB.2MA0620-074R","volume":"108","author":"J Rautela","year":"2020","unstructured":"Rautela J, Surgenor E, Huntington ND. Drug target validation in primary human natural killer cells using CRISPR RNP. J Leukoc Biol. 2020;108(4):1397\u2013408.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"2770_CR29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ymthe.2019.10.009","volume":"28","author":"EJ Pomeroy","year":"2020","unstructured":"Pomeroy EJ, Hunzeker JT, Kluesner MG, Lahr WS, Smeester BA, Crosby MR, et al. A genetically engineered primary human natural killer cell platform for cancer immunotherapy. Mol Ther. 2020;28(1):52\u201363.","journal-title":"Mol Ther"},{"issue":"3","key":"2770_CR30","doi-asserted-by":"crossref","first-page":"e0212455","DOI":"10.1371\/journal.pone.0212455","volume":"14","author":"Y Tanaka","year":"2019","unstructured":"Tanaka Y, Nakazawa T, Nakamura M, Nishimura F, Matsuda R, Omoto K, et al. Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro. PLoS ONE. 2019;14(3):e0212455.","journal-title":"PLoS ONE"},{"issue":"11","key":"2770_CR31","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1111\/cas.14621","volume":"111","author":"Y Kobayashi","year":"2020","unstructured":"Kobayashi Y, Kushihara Y, Saito N, Yamaguchi S, Kakimi K. A novel scoring method based on RNA-Seq immunograms describing individual cancer-immunity interactions. Cancer Sci. 2020;111(11):4031\u201340.","journal-title":"Cancer Sci"},{"issue":"1","key":"2770_CR32","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/neuonc\/now247","volume":"19","author":"RL Bowman","year":"2017","unstructured":"Bowman RL, Wang Q, Carro A, Verhaak RG, Squatrito M. GlioVis data portal for visualization and analysis of brain tumor expression datasets. Neuro Oncol. 2017;19(1):139\u201341.","journal-title":"Neuro Oncol"},{"issue":"7","key":"2770_CR33","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.3390\/ijms22073489","volume":"22","author":"T Morimoto","year":"2021","unstructured":"Morimoto T, Nakazawa T, Matsuda R, Nishimura F, Nakamura M, Yamada S, et al. CRISPR-Cas9-mediated TIM3 knockout in human natural killer cells enhances growth inhibitory effects on human glioma cells. Int J Mol Sci. 2021;22(7):3489.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2770_CR34","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/cells9040998","volume":"9","author":"T Nakazawa","year":"2020","unstructured":"Nakazawa T, Natsume A, Nishimura F, Morimoto T, Matsuda R, Nakamura M, et al. Effect of CRISPR\/Cas9-mediated PD-1-disrupted primary human third-generation CAR-T cells targeting EGFRvIII on in vitro human glioblastoma cell growth. Cells. 2020;9(4):998.","journal-title":"Cells"},{"issue":"2","key":"2770_CR35","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10616-014-9692-5","volume":"67","author":"M Roshan Moniri","year":"2015","unstructured":"Roshan Moniri M, Young A, Reinheimer K, Rayat J, Dai LJ, Warnock GL. Dynamic assessment of cell viability, proliferation and migration using real time cell analyzer system (RTCA). Cytotechnology. 2015;67(2):379\u201386.","journal-title":"Cytotechnology"},{"key":"2770_CR36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.reth.2022.07.001","volume":"21","author":"T Nakazawa","year":"2022","unstructured":"Nakazawa T, Morimoto T, Maeoka R, Matsuda R, Nakamura M, Nishimura F, et al. Establishment of an efficient ex vivo expansion strategy for human natural killer cells stimulated by defined cytokine cocktail and antibodies against natural killer cell activating receptors. Regen Ther. 2022;21:185\u201391.","journal-title":"Regen Ther"},{"issue":"2","key":"2770_CR37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3171\/jns.1989.70.2.0175","volume":"70","author":"D Barba","year":"1989","unstructured":"Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg. 1989;70(2):175\u201382.","journal-title":"J Neurosurg"},{"issue":"3b","key":"2770_CR38","first-page":"1861","volume":"24","author":"E Ishikawa","year":"2004","unstructured":"Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T, et al. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res. 2004;24(3b):1861\u201371.","journal-title":"Anticancer Res"},{"issue":"9","key":"2770_CR39","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1172\/JCI129338","volume":"129","author":"JJ Hodgins","year":"2019","unstructured":"Hodgins JJ, Khan ST, Park MM, Auer RC, Ardolino M. Killers 2.0: NK cell therapies at the forefront of cancer control. J Clin Invest. 2019;129(9):3499\u2013510.","journal-title":"J Clin Invest"},{"issue":"1","key":"2770_CR40","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1146\/annurev-cancerbio-030518-055653","volume":"3","author":"JS Miller","year":"2019","unstructured":"Miller JS, Lanier LL. Natural killer cells in cancer immunotherapy. Annu Rev Cancer Biol. 2019;3(1):77\u2013103.","journal-title":"Annu Rev Cancer Biol"},{"key":"2770_CR41","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.2147\/OTT.S139986","volume":"10","author":"S Liang","year":"2017","unstructured":"Liang S, Xu K, Niu L, Wang X, Liang Y, Zhang M, et al. Comparison of autogeneic and allogeneic natural killer cells immunotherapy on the clinical outcome of recurrent breast cancer. Onco Targets Ther. 2017;10:4273\u201381.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"2770_CR42","doi-asserted-by":"crossref","first-page":"7656","DOI":"10.1038\/s41598-023-34827-z","volume":"13","author":"EK Koh","year":"2023","unstructured":"Koh EK, Lee HR, Son WC, Park GY, Kim J, Bae JH, et al. Combinatorial immunotherapy with gemcitabine and ex vivo-expanded NK cells induces anti-tumor effects in pancreatic cancer. Sci Rep. 2023;13(1):7656.","journal-title":"Sci Rep"},{"issue":"1","key":"2770_CR43","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","volume":"106","author":"C Imai","year":"2005","unstructured":"Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106(1):376\u201383.","journal-title":"Blood"},{"issue":"1","key":"2770_CR44","doi-asserted-by":"crossref","first-page":"11075","DOI":"10.1038\/s41598-017-09259-1","volume":"7","author":"HR Lee","year":"2017","unstructured":"Lee HR, Son CH, Koh EK, Bae JH, Kang CD, Yang K, et al. Expansion of cytotoxic natural killer cells using irradiated autologous peripheral blood mononuclear cells and anti-CD16 antibody. Sci Rep. 2017;7(1):11075.","journal-title":"Sci Rep"},{"issue":"4","key":"2770_CR45","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.intimp.2012.09.014","volume":"14","author":"X Deng","year":"2012","unstructured":"Deng X, Terunuma H, Nieda M, Xiao W, Nicol A. Synergistic cytotoxicity of ex vivo expanded natural killer cells in combination with monoclonal antibody drugs against cancer cells. Int Immunopharmacol. 2012;14(4):593\u2013605.","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"2770_CR46","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1349-7006.2006.00319.x","volume":"97","author":"MZ Dewan","year":"2006","unstructured":"Dewan MZ, Terunuma H, Toi M, Tanaka Y, Katano H, Deng X, et al. Potential role of natural killer cells in controlling growth and infiltration of AIDS-associated primary effusion lymphoma cells. Cancer Sci. 2006;97(12):1381\u20137.","journal-title":"Cancer Sci"},{"issue":"2","key":"2770_CR47","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1615\/CritRevImmunol.2016017387","volume":"36","author":"AY Mah","year":"2016","unstructured":"Mah AY, Cooper MA. Metabolic regulation of natural killer cell IFN-gamma production. Crit Rev Immunol. 2016;36(2):131\u201347.","journal-title":"Crit Rev Immunol"},{"issue":"8","key":"2770_CR48","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/ni.2936","volume":"15","author":"A Marcais","year":"2014","unstructured":"Marcais A, Cherfils-Vicini J, Viant C, Degouve S, Viel S, Fenis A, et al. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. Nat Immunol. 2014;15(8):749\u201357.","journal-title":"Nat Immunol"},{"issue":"5","key":"2770_CR49","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41577-019-0139-2","volume":"19","author":"KL O'Brien","year":"2019","unstructured":"O\u2019Brien KL, Finlay DK. Immunometabolism and natural killer cell responses. Nat Rev Immunol. 2019;19(5):282\u201390.","journal-title":"Nat Rev Immunol"},{"issue":"6155","key":"2770_CR50","doi-asserted-by":"crossref","first-page":"1242454","DOI":"10.1126\/science.1242454","volume":"342","author":"EL Pearce","year":"2013","unstructured":"Pearce EL, Poffenberger MC, Chang CH, Jones RG. Fueling immunity: insights into metabolism and lymphocyte function. Science. 2013;342(6155):1242454.","journal-title":"Science"},{"issue":"1","key":"2770_CR51","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3109\/14653249.2010.515582","volume":"13","author":"MA Geller","year":"2011","unstructured":"Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13(1):98\u2013107.","journal-title":"Cytotherapy"},{"key":"2770_CR52","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molimm.2017.11.021","volume":"115","author":"T Kobayashi","year":"2019","unstructured":"Kobayashi T, Mattarollo SR. Natural killer cell metabolism. Mol Immunol. 2019;115:3\u201311.","journal-title":"Mol Immunol"},{"issue":"4","key":"2770_CR53","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.4049\/jimmunol.1402099","volume":"194","author":"MP Keppel","year":"2015","unstructured":"Keppel MP, Saucier N, Mah AY, Vogel TP, Cooper MA. Activation-specific metabolic requirements for NK Cell IFN-gamma production. J Immunol. 2015;194(4):1954\u201362.","journal-title":"J Immunol"},{"issue":"9","key":"2770_CR54","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.4049\/jimmunol.1401558","volume":"193","author":"RP Donnelly","year":"2014","unstructured":"Donnelly RP, Loftus RM, Keating SE, Liou KT, Biron CA, Gardiner CM, et al. mTORC1-dependent metabolic reprogramming is a prerequisite for NK cell effector function. J Immunol. 2014;193(9):4477\u201384.","journal-title":"J Immunol"},{"issue":"11","key":"2770_CR55","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1182\/blood-2016-02-698027","volume":"128","author":"Y Mao","year":"2016","unstructured":"Mao Y, van Hoef V, Zhang X, Wennerberg E, Lorent J, Witt K, et al. IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells. Blood. 2016;128(11):1475\u201389.","journal-title":"Blood"},{"issue":"2","key":"2770_CR56","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cmet.2018.06.021","volume":"28","author":"J Cong","year":"2018","unstructured":"Cong J, Wang X, Zheng X, Wang D, Fu B, Sun R, et al. Dysfunction of natural killer cells by FBP1-induced inhibition of glycolysis during lung cancer progression. Cell Metab. 2018;28(2):243-55 e5.","journal-title":"Cell Metab"},{"issue":"12","key":"2770_CR57","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1038\/s41590-018-0251-7","volume":"19","author":"X Michelet","year":"2018","unstructured":"Michelet X, Dyck L, Hogan A, Loftus RM, Duquette D, Wei K, et al. Metabolic reprogramming of natural killer cells in obesity limits antitumor responses. Nat Immunol. 2018;19(12):1330\u201340.","journal-title":"Nat Immunol"},{"issue":"1","key":"2770_CR58","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.tcb.2003.11.001","volume":"14","author":"DT Rutkowski","year":"2004","unstructured":"Rutkowski DT, Kaufman RJ. A trip to the ER: coping with stress. Trends Cell Biol. 2004;14(1):20\u20138.","journal-title":"Trends Cell Biol"},{"issue":"7203","key":"2770_CR59","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nature07203","volume":"454","author":"K Zhang","year":"2008","unstructured":"Zhang K, Kaufman RJ. From endoplasmic-reticulum stress to the inflammatory response. Nature. 2008;454(7203):455\u201362.","journal-title":"Nature"},{"issue":"1\u20132","key":"2770_CR60","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.mrfmmm.2004.06.056","volume":"569","author":"M Schroder","year":"2005","unstructured":"Schroder M, Kaufman RJ. ER stress and the unfolded protein response. Mutat Res. 2005;569(1\u20132):29\u201363.","journal-title":"Mutat Res"},{"issue":"10","key":"2770_CR61","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1172\/JCI0216784","volume":"110","author":"D Ron","year":"2002","unstructured":"Ron D. Translational control in the endoplasmic reticulum stress response. J Clin Invest. 2002;110(10):1383\u20138.","journal-title":"J Clin Invest"},{"issue":"10","key":"2770_CR62","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1172\/JCI0216886","volume":"110","author":"RJ Kaufman","year":"2002","unstructured":"Kaufman RJ. Orchestrating the unfolded protein response in health and disease. J Clin Invest. 2002;110(10):1389\u201398.","journal-title":"J Clin Invest"},{"issue":"5","key":"2770_CR63","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1097-2765(00)00108-8","volume":"6","author":"HP Harding","year":"2000","unstructured":"Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M, et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell. 2000;6(5):1099\u2013108.","journal-title":"Mol Cell"},{"issue":"14","key":"2770_CR64","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.1128\/MCB.20.14.5096-5106.2000","volume":"20","author":"M Li","year":"2000","unstructured":"Li M, Baumeister P, Roy B, Phan T, Foti D, Luo S, et al. ATF6 as a transcription activator of the endoplasmic reticulum stress element: thapsigargin stress-induced changes and synergistic interactions with NF-Y and YY1. Mol Cell Biol. 2000;20(14):5096\u2013106.","journal-title":"Mol Cell Biol"},{"issue":"50","key":"2770_CR65","doi-asserted-by":"crossref","first-page":"33741","DOI":"10.1074\/jbc.273.50.33741","volume":"273","author":"H Yoshida","year":"1998","unstructured":"Yoshida H, Haze K, Yanagi H, Yura T, Mori K. Identification of the cis-acting endoplasmic reticulum stress response element responsible for transcriptional induction of mammalian glucose-regulated proteins. Involvement of basic leucine zipper transcription factors. J Biol Chem. 1998;273(50):33741\u20139.","journal-title":"J Biol Chem"},{"issue":"1","key":"2770_CR66","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1083\/jcb.150.1.77","volume":"150","author":"DT Ng","year":"2000","unstructured":"Ng DT, Spear ED, Walter P. The unfolded protein response regulates multiple aspects of secretory and membrane protein biogenesis and endoplasmic reticulum quality control. J Cell Biol. 2000;150(1):77\u201388.","journal-title":"J Cell Biol"},{"issue":"3","key":"2770_CR67","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0092-8674(00)80835-1","volume":"101","author":"KJ Travers","year":"2000","unstructured":"Travers KJ, Patil CK, Wodicka L, Lockhart DJ, Weissman JS, Walter P. Functional and genomic analyses reveal an essential coordination between the unfolded protein response and ER-associated degradation. Cell. 2000;101(3):249\u201358.","journal-title":"Cell"},{"issue":"5","key":"2770_CR68","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","volume":"172","author":"JP Bottcher","year":"2018","unstructured":"Bottcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell. 2018;172(5):1022\u20133714.","journal-title":"Cell"},{"issue":"7822","key":"2770_CR69","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41586-020-2611-3","volume":"584","author":"ST Ferris","year":"2020","unstructured":"Ferris ST, Durai V, Wu R, Theisen DJ, Ward JP, Bern MD, et al. cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity. Nature. 2020;584(7822):624\u20139.","journal-title":"Nature"},{"key":"2770_CR70","doi-asserted-by":"publisher","unstructured":"Bernard PL, Delconte R, Pastor S, Laletin V, Costa Da Silva C, Goubard A, et al. Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity. J Immunother Cancer. 2022;10(5):e004244. https:\/\/doi.org\/10.1136\/jitc-2021-004244.","DOI":"10.1136\/jitc-2021-004244"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02770-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-023-02770-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02770-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:48:55Z","timestamp":1700527735000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-023-02770-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2770"],"URL":"https:\/\/doi.org\/10.1186\/s13046-023-02770-6","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]},"assertion":[{"value":"8 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This Ethics Committee of Nara Medical University approved this study (No. 1058). The study was conducted according to university guidelines. All procedures that involved human participants were conducted according to institutional and\/or national research committee ethical standards and the 1964 Declaration of Helsinki and its subsequent alterations or equivalent ethical standards. All healthy volunteers in this study provided informed consent in accordance with Declaration of Helsinki tenets.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and agreed to the published version of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"T.N. and M.N. are employees of Grandsoul Research Institute for Immunology, Inc. and Clinic Grandsoul Nara, respectively. The other authors declare no conflicts of interest. There are no competing financial interests in relation to the work described.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"205"}}